Le rapport
Actualités vérifiées sur le financement, les sièges sociaux et les dirigeants des entreprises les plus innovantes au monde
353 rapports et plus encore
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ande Emerges From Stealth With $52M in Seed and Series A Funding
Ande launched with more than $52 million from Lightspeed, Redpoint, Duration, Sierra Ventures, and Bain Capital Ventures for enterprise entertainment spend.
MIND Raises $72M Series B for AI-Native Data Loss Prevention
MIND raised a $72 million Series B led by Crosspoint Capital Partners, bringing total funding to $112 million for its AI-native DLP platform.
Riverlane Establishes US Headquarters in Maryland
Quantum-error-correction company Riverlane is establishing its US headquarters with office and laboratory space in College Park, Maryland.
Profound Raises $180M Series D at a $1.8B Valuation
Profound raised a $180 million Series D co-led by Sequoia and Kleiner Perkins to expand its AI platform for enterprise marketing teams.
Levanta Raises $22M Series B for Creator Commerce Infrastructure
Levanta raised a $22 million Series B led by Volition Capital, bringing total funding above $43 million as it expands across retail marketplaces.
Infinimmune Raises $75M Series A for Human-Derived Antibody Drugs
Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.
Aureka Biotechnologies Raises $100M Series B for Biological Foundation Models
Aureka Biotechnologies closed a $100 million Series B to train biological foundation models and expand its experiment-centered drug-discovery platform.
Expedition Therapeutics Raises $115M Series B for Oral DPP1 Inhibitor for COPD
Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.
Affichage de 9 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.